SBFM
ALNY icon

S-Bank Fund Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

S-Bank Fund Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$555K Buy
1,844
+609
+49% +$184K 0.08% 141
2026
Q1 		$409K Sell
1,235
-46
-4% -$15.7K 0.06% 126
2025
Q4 		$509K Sell
1,281
-312
-20% -$138K 0.07% 115
2025
Q3 		$726K Sell
1,593
-21
-1% -$8.55K 0.1% 119
2025
Q2 		$526K Sell
1,614
-146
-8% -$40.4K 0.08% 143
2025
Q1 		$475K Buy
+1,760
New +$452K 0.09% 124

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

S-Bank Fund Management's ALNY Position: Q2 2026 in Review

S-Bank Fund Management increased its Alnylam Pharmaceuticals (ALNY) stake by 49% in Q2 2026, buying an estimated $184K and bringing the position to 1,844 shares worth $555K. The position accounts for 0.08% of the portfolio, ranked #141.

S-Bank Fund Management first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. The position peaked at $726K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • S-Bank Fund Management held 1,844 shares of Alnylam Pharmaceuticals worth $555K as of Q2 2026.
  • S-Bank Fund Management bought 609 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $184K.
  • Alnylam Pharmaceuticals made up 0.08% of S-Bank Fund Management's portfolio in Q2 2026, its #141 holding.
  • S-Bank Fund Management first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • S-Bank Fund Management's Alnylam Pharmaceuticals position peaked at $726K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on S-Bank Fund Management's 13F filing for Q2 2026, filed 4 Aug 2026.